Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605518 | 0.89 | SLC2A1 (0.49) | SLC2A1BCHEKDM4ELMNAHTT | |
| SCHEMBL8315122 | 0.83 | ALDH1A1 (0.62) | LMNAHTTKMT2AALDH1A1MEN1 | |
| SCHEMBL10702781 | 0.81 | SLC2A1 (0.69) | SLC2A1BCHEKDM4ELMNAHTT | |
| SCHEMBL31241513 | 0.81 | CHRM2 (0.52) | BCHEKDM4ELMNAKMT2AMEN1 | |
| SCHEMBL7279749 | 0.80 | SLC2A1 (0.89) | SLC2A1BCHEKDM4ELMNAHTT | |
| SCHEMBL2444736 | 0.79 | DPP7 (0.69) | KMT2AALDH1A1MEN1 | |
| SCHEMBL14691619 | 0.79 | SLC2A1 (0.73) | SLC2A1BCHEKDM4ELMNAHTT | |
| SCHEMBL29721229 | 0.79 | SLC2A1 (0.73) | SLC2A1BCHEKDM4ELMNAHTT | |
| Hydrochloric Acid SCHEMBL18529888 | 0.78 | SLC2A1 (0.71) | SLC2A1BCHEKDM4ELMNAHTT | |
| Hydrochloric Acid SCHEMBL29721109 | 0.78 | SLC2A1 (0.71) | SLC2A1BCHEKDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809288-B1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INST NAT SANTE RECH MED (FR) | 2011-09-14 | — | — | EP | claimed |
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | UNIVERSITE DU DROIT ET DE LA SANTE- LILLE II (FR) | 2009-06-11 | — | — | US | claimed |
| EP-1809288-A1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2007-07-25 | — | — | EP | claimed |
| WO-2006051489-A1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-05-18 | — | — | WO | claimed |
| US-9044478-B2 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2015-06-02 | — | — | US | disclosed |
| EP-1809288-B1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INST NAT SANTE RECH MED (FR) | 2011-09-14 | — | — | EP | disclosed |
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | UNIVERSITE DU DROIT ET DE LA SANTE- LILLE II (FR) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | PSEN1, PSEN2, SNCA | SLC2A1 2624/4885BCHE 375/4885KDM4E 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.